Thermosome Initiates Final Dose Level in Phase I Trial of Lead Compound THE001 Independent Data Safety Monitoring Board declared dose level 2 as safe and recommended escalation to final dose level 3 Munich, Germany – December 4, 2024 – Thermosome, a drug development company...

Thermosome Announces Further Dose Escalation in Phase I Trial with Lead Program THE001 -    First dose level rated as safe by independent Data Safety Monitoring Board-    Second dose level to be administered according to plan-    THE001 designed as targeted tumor treatment independent...